MarketGrader Europe 100 Index


Five Largest Companies
Symbol Name Grade Market Cap Country
ASML.NL ASML Holding NV 62.5 ¤547,667 NL
HSBA.GB HSBC Holdings Plc 50.2 ¤298,657 GB
AZN.GB AstraZeneca PLC 68.7 ¤285,742 GB
NOVN.CH Novartis AG 59.5 ¤280,661 CH
NOVO.B.DK Novo Nordisk A/S Class B 59.2 ¤261,181 DK

Five Smallest Companies
Symbol Name Grade Market Cap Country
BIM.FR bioMerieux SA 50.2 ¤13,680 FR
SN.GB Smith & Nephew plc 60.7 ¤14,104 GB
ENX.FR Euronext NV 55.5 ¤14,121 NL
SOON.CH Sonova Holding AG 48.7 ¤16,240 CH
PNR Pentair plc 55.2 ¤17,331 GB

Companies with Most Selections Among Current Components
Symbol Name Grade Times* Country
ASML.NL ASML Holding NV 62.5 33 NL
ACN Accenture Plc Class A 59.3 32 IE
DNB.NO DNB Bank ASA 59.8 29 NO
ALV.DE Allianz SE 51.2 28 DE
LR.FR Legrand SA 55.7 28 FR
NOVO.B.DK Novo Nordisk A/S Class B 59.2 28 DK
ASSA.B.SE ASSA ABLOY AB Class B 54.0 27 SE
TEL TE Connectivity plc 65.6 26 IE
ETN Eaton Corp. Plc 57.8 25 IE
SAND.SE Sandvik AB 51.9 24 SE
*Number of times selected at Index semi-annual reconstitutions since inception date.
Index Bio
Average Market Cap ¤77,230
Median Market Cap ¤45,313
Avg. 3 Mo. Dollar Vol. ¤164,044,480
Avg. 3 Mo. Trading Vol. 5,308,741
Last Rebalance Date 09/22/2025
Companies Replaced 49
Biggest Sector Increase Health Care
Biggest Sector Decrease Utilities

Fundamental Attributes
Trailing P/E Ratio (12 Mo.) 18.4
Forward P/E Ratio (12 Mo.) 15.3
Price/Book Ratio 3.2
Avg. Revenue Chg. - 3 Yr 25.7%
Avg. Op. Income Chg. - 3 Yr. 52.3%
Avg. EPS Growth - 3 Yr. 16.3%
Avg. EPS Growth - 1 Yr. 19.6%
Avg. Operating Margin 19.6%
Avg. LT Debt to Total Capital 40.3%
Avg. Return on Equity 16.8%
Dividend Yield 1.9%
Index Average Grade
Europe 100 Index 57.82
Country Breakdown
United Kingdom 22.0%
Germany 14.0%
Switzerland 10.0%
Ireland 10.0%
Netherlands 9.0%
Sweden 7.0%
France 7.0%
Italy 6.0%
Spain 5.0%
Denmark 2.0%
Belgium 2.0%
Norway 2.0%
Luxembourg 1.0%
Hong Kong 1.0%
Austria 1.0%
Finland 1.0%
For more information on this index please contact us

Get Access to the World's Smartest Global Research Platform

Don't wait another day to make better informed, higher-returning investments.

TRY IT FOR FREE